Have a feature idea you'd love to see implemented?
Let us know!
CMRX Chimerix Inc
Price (delayed)
$0.9137
Market cap
$82.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$59.17M
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious
Highlights
The debt has plunged by 56% YoY and by 22% from the previous quarter
Chimerix's revenue has plunged by 86% YoY but it has increased by 10% from the previous quarter
The company's gross profit has shrunk by 86% YoY but it rose by 10% QoQ
CMRX's quick ratio has dropped by 51% year-on-year and by 9% since the previous quarter
The equity has declined by 35% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of CMRX
Market
Valuations
Earnings
Shares outstanding
89.94M
Market cap
$82.17M
Enterprise value
$59.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.6
Price to sales (P/S)
515.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
372.16
Revenue
$159,000
EBIT
-$83.59M
EBITDA
-$83.61M
Free cash flow
-$70.42M
Per share
Balance sheet
Liquidity
EPS
-$0.95
Free cash flow per share
-$0.79
Book value per share
$1.51
Revenue per share
$0
TBVPS
$1.77
Total assets
$158.67M
Total liabilities
$22.89M
Debt
$644,000
Equity
$135.78M
Working capital
$118.66M
Debt to equity
0
Current ratio
6.33
Quick ratio
6.13
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
-52,585.5%
Gross margin
100%
Net margin
-52,574.8%
Operating margin
-58,380.5%
Return on assets
-44.9%
Return on equity
-50.8%
Return on invested capital
-57.6%
Return on capital employed
-61.3%
Return on sales
-52,574.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMRX stock price
How has the Chimerix stock price performed over time
Intraday
3.83%
1 week
1.67%
1 month
3.83%
1 year
-4.82%
YTD
-5.07%
QTD
-1.75%
Financial performance
How have Chimerix's revenue and profit performed over time
Revenue
$159,000
Gross profit
$159,000
Operating income
-$92.83M
Net income
-$83.59M
Gross margin
100%
Net margin
-52,574.8%
Chimerix's revenue has plunged by 86% YoY but it has increased by 10% from the previous quarter
The company's gross profit has shrunk by 86% YoY but it rose by 10% QoQ
The net margin has grown by 11% from the previous quarter
The company's operating margin rose by 11% QoQ
Growth
What is Chimerix's growth rate over time
Valuation
What is Chimerix stock price valuation
P/E
N/A
P/B
0.6
P/S
515.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
372.16
The stock's price to book (P/B) is 78% less than its 5-year quarterly average of 2.7 but 20% more than its last 4 quarters average of 0.5
The equity has declined by 35% year-on-year and by 13% since the previous quarter
Chimerix's revenue has plunged by 86% YoY but it has increased by 10% from the previous quarter
CMRX's P/S is 84% higher than its 5-year quarterly average of 279.5 but 43% lower than its last 4 quarters average of 910.2
Efficiency
How efficient is Chimerix business performance
Chimerix's ROIC has decreased by 47% YoY and by 13% from the previous quarter
Chimerix's return on equity has decreased by 39% YoY and by 10% QoQ
CMRX's return on assets is down by 33% year-on-year and by 7% since the previous quarter
The ROS has grown by 11% from the previous quarter
Dividends
What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMRX.
Financial health
How did Chimerix financials performed over time
The current ratio has dropped by 51% year-on-year and by 9% since the previous quarter
CMRX's quick ratio has dropped by 51% year-on-year and by 9% since the previous quarter
The debt is 100% less than the equity
The debt to equity has shrunk by 100% QoQ and by 100% YoY
The debt has plunged by 56% YoY and by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.